Agios Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 22 Posts
1 2
Biotechs Hold And Ignore Rocky Week Of Global Politics - Big Earnings Upcoming… Updates CELG, BIIB, AZN, XBI
Article By: Rod Raynovich Saturday, July 28, 2018 9:15 PM EDT
Biotech and Tech stocks teetered near highs for the year despite all the political drama of Putin and Trump at Helsinki, Russian “Spy” at the NRA, Tariffs and Trade War, Brexit Uncertainty, currency volatility and the Powell FED rate hike policy.
In this article: AZN, BIIB, LLY, CELG, RHHBY, VRTX, BMY, AMGN, GILD, ABBV, HON, JNJ, AGIO
Read
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
Article By: ChinaBio® Today Saturday, June 30, 2018 4:25 PM EDT
CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios in a deal worth up to $424 million. CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia (AML) and cholangiocarcinoma.
In this article: AGIO, LGND, NVS, ZLAB
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Biotechs Bounce Off Bottom On Novartis Deal But Fade Later In The Day
Article By: Rod Raynovich Monday, April 9, 2018 7:49 PM EDT
Normally this kind of M&A news would be an opportunity to load up on biotechs but technicals are still weak and crosscurrents from economic and macro news create a risk-off sentiment.
In this article: NVS, FBT, AGIO, AVXS Also: IBB, SGMO, XBI, BLUE, ONCE, CLLS, EDIT, NTLA, CRSP
Read
4 Medical Product Stocks Likely To Top Q2 Earnings Estimates
Article By: Zacks Investment Research Monday, August 7, 2017 5:52 PM EDT
With the existence of a number of industry players, finding the right stocks that have the potential to beat earnings could be a daunting task.
In this article: XRAY, AGIO, NVTR, DXTR
Read
Rayno Biobeat 2017 #1: Biotech Rally Driven By M&A
Article By: Rod Raynovich Friday, February 10, 2017 4:00 PM EDT
Biogen looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI​ slight gains.
In this article: ACOR, ALNY, ARRY, IBB, REGN, SGEN, AMGN, BIIB, CLVS, HOLX, XBI, AGIO, BLUE, FMI, TSRO
Read
Actelion Remains In M&A Spotlight, ASH Data In Focus
Article By: Arpita Dutt Wednesday, December 7, 2016 6:01 PM EDT
Switzerland-based Actelion continued to be a part of acquisition chatter with Sanofi now rumored to be interested in the company.
In this article: ALIOF, AMGN, CELG, VRTX, ABBV, AGIO, KITE
Read
Stealth Biotech Rally With Momentum Rising
Article By: Rod Raynovich Wednesday, September 21, 2016 2:20 AM EDT
Biotechs stocks continued on their slow but steady upward course headed toward August highs in the case of the IBB and breaking out with the smaller cap weighted XBI​.
In this article: AGN, RHHBY, ARIA, IBB, MDVN, SGEN, AMGN, CLVS, GILD, XBI, PBYI, ABBV, SRPT, AGIO, BLUE, TBRA
Read
Short Setups I Am Watching This Week - July 19, 2016
Article By: Ryan Mallory Tuesday, July 19, 2016 2:31 PM EDT
The market is trading sideways the past couple of days. I don't see that being bearish at this point. Especially when you consider the ramp the market has been on since the Brexit sell-off.
In this article: AL, BLL, BNS, BWA, CBG, COP, DAL, DAN, DB, DK, LPI, MAN, MET, MFC, MGA, PRU, RCL, RHT, SEM, SM, XPO, ADSK, ZION, FET, FOX, FOXA, AGIO
Read
Syros Pharmaceuticals: Despite High-Demand Treatments, We Remain Cautious
Article By: Don Dion Wednesday, July 6, 2016 9:17 PM EDT
Based in Watertown, Massachusetts, Syros Pharmaceuticals is a biopharmaceutical company that is developing treatments to control genes in patients with cancer, immune-mediated diseases, and other illnesses.
In this article: NVS, AGIO, KPTI, SYRS
Read
Biotech Recovery Rally: Steady As She Goes-Biogen Rallies On Earnings
Article By: Rod Raynovich Thursday, April 21, 2016 5:11 PM EDT
Biotech shares have beat the market and the QQQ up 2.48% over one month but are still recovering from the January free fall with lows in mid-February.
In this article: IBB, INCY, BIIB, GILD, XBI, XLV, AGIO, BLUE, QQQ
Read
Large Cap Biotech Stocks Get Traction From Revenue Growth
Article By: Rod Raynovich Tuesday, October 27, 2015 9:34 PM EDT
Strong overall biotech tape today, with healthcare as leading sector. Biopharma and healthcare stocks firmed up today helped by Biogen earnings last week and today again with Gilead Sciences.
In this article: BMY, CPHD, IBB, INCY, QQQ, AMGN, BIIB, GILD, XBI, PBYI, AGIO
Read
Biotech Stocks Sell-Off On China, Greece And Network Outages
Article By: Rod Raynovich Wednesday, July 8, 2015 10:00 PM EDT
Biotech stocks have stalled recently after hitting all time highs in late June. With not many news drivers ahead for life science stocks wait for earnings results and watch technicals. Risk remains off.
In this article: AGIO, AMGN, ANLY, BIIB, BLUE, BMRN, CLVS, EWJ, GILD, INCY, JUNO, KITE, REGN, VRTX, XBI, ZIOP
Read
What Sell-Off? Biotechs Cruise: CLVS, SGEN
Article By: Rod Raynovich Wednesday, March 11, 2015 3:41 AM EDT
Biotech stocks avoided the severe sell-off today apparently immune to the strong dollar, flat earnings growth and FED interest rate concerns. Although life science stocks were mixed the bellwether ETFs held their ground.
In this article: SLVSY, SGEN, SPY, QQQ, FBT, XBI, XLV, AGIO, ALNY, BLUE, MDVN, PBYI, UUP
Read
A Company's First Profit Can Mean Big Profits To Investors
Article By: Kevin Matras Wednesday, January 14, 2015 7:32 AM EDT
With earnings season having just begun, now is a great time to take a look at my 'First Profit' stock screen. The concept for this one is to find companies that have recently shown their first quarterly profit within the last year.
In this article: OPHT, XNPT, OSUR, INCY, AGIO
Read
Bull Of The Day: Incyte
Article By: Kevin Cook Friday, January 2, 2015 8:19 AM EDT
INCY is a $12 billion pharmaceutical company that is expected to finally turn a profit next year on the success of its drug Jakafi, the only FDA - approved treatment for myelofibrosis (MF).
In this article: INCY, ABBV, PCYC, GILD, SGEN, AGIO
Read
1 to 16 of 22 Posts
1 2